About Leucine-rich repeat-containing protein 23
Leucine-rich repeat-containing protein 23 (LRRC23) is a protein
from Homo sapiens identified by UniProt accession
Q53EV4, 343 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | Leucine-rich repeat-containing protein 23 |
| UniProt accession | Q53EV4 |
| Gene | LRRC23 |
| Organism | Homo sapiens |
| Length | 343 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (109)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.20
- nitric oxide exhalation measurement · score 0.15
- self reported educational attainment · score 0.14
- systolic blood pressure · score 0.14
- genetic disorder · score 0.12
- azoospermia · score 0.11
- male infertility with teratozoospermia due to single gene mutation · score 0.10
- colorectal cancer · score 0.09
- spermatogenic failure 49 · score 0.09
- spermatogenic failure 43 · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q53EV4-F1 | alphafold | PREDICTED | 88.22 | — |
Amino-acid sequence (343 residues)
MSDEDDLEDS EPDQDDSEKE EDEKETEEGE DYRKEGEEFP EEWLPTPLTE DMMKEGLSLL CKTGNGLAHA YVKLEVKERD LTDIYLLRSY IHLRYVDISE NHLTDLSPLN YLTHLLWLKA DGNRLRSAQM NELPYLQIAS FAYNQITDTE GISHPRLETL NLKGNSIHMV TGLDPEKLIS LHTVELRGNQ LESTLGINLP KLKNLYLAQN MLKKVEGLED LSNLTTLHLR DNQIDTLSGF SREMKSLQYL NLRGNMVANL GELAKLRDLP KLRALVLLDN PCTDETSYRQ EALVQMPYLE RLDKEFYEEE ERAEADVIRQ RLKEEKEQEP EPQRDLEPEQ SLI
Explore Leucine-rich repeat-containing protein 23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets